Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$563.00 USD

563.00
1,024,320

+3.20 (0.57%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $563.06 +0.06 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Regeneron, Teva Announce Positive Data on Osteoarthritis Drug

by Zacks Equity Research

Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.

    Zacks Equity Research

    Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study

    by Zacks Equity Research

    Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.

      Zacks Equity Research

      Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD

      by Zacks Equity Research

      Regeneron (REGN) suffers setback as the FDA issues a CRL to its application for label expansion of Eylea for wet AMD with a modified 12-week dosing schedule.

        Zacks Equity Research

        Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential

        by Zacks Equity Research

        Regeneron Pharmaceuticals (REGN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.

          Zacks Equity Research

          Momenta (MNTA) Earnings and Revenues Lag Estimates in Q2

          by Zacks Equity Research

          Momenta (MNTA) reports wider-than-expected Q2 loss. Sales miss estimates too. The focus now is on the outcome of the ongoing strategic review including a possible sale of the biosimilar business.

            Zacks Equity Research

            Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales

            by Zacks Equity Research

            Sarepta's (SRPT) loss per share is narrower than the Zacks Consensus Estimate while sales also beat the same. Exondys 51 continues its strong performance.

              Zacks Equity Research

              Inovio (INO) Q2 Loss Narrows, Revenues Surpass Estimates

              by Zacks Equity Research

              Inovio's (INO) Q2 loss betters estimates. Also, the company rides high on revenue beat.

                Zacks Equity Research

                Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges

                by Zacks Equity Research

                The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.

                  Ryan McQueeney headshot

                  T-Mobile-Sprint, Pepsi CEO Departs, Jamie Dimon's Latest Wisdom, & More | Free Lunch

                  by Ryan McQueeney

                  Ryan McQueeney highlights today's trending stories, including the departure of PepsiCo's CEO, Jamie Dimon's latest public wisdom, and Bluebird Bio's new partnership. Later, he recaps recent developments in the T-Mobile-Sprint merger and previews what the combined company might look like.

                    Ryan McQueeney headshot

                    Why Is Bluebird Bio (BLUE) Stock Gaining Today?

                    by Ryan McQueeney

                    Shares of Bluebird Bio (BLUE) gained in morning trading Monday after the company announced a new partnership with Regeneron Pharmaceuticals (REGN). The five-year agreement will see both firms collaborate on new cell therapies for the treatment of cancer.

                      Zacks Equity Research

                      Company News For Aug 3, 2018

                      by Zacks Equity Research

                      Companies in the news are: CI, TSLA, TEVA and REGN

                        Zacks Equity Research

                        Regeneron Pharmaceuticals (REGN) Jumps: Stock Rises 7%

                        by Zacks Equity Research

                        Regeneron Pharmaceuticals (REGN) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

                          Zacks Equity Research

                          Zoetis (ZTS) Beats on Q2 Earnings & Sales, Updates '18 View

                          by Zacks Equity Research

                          Zoetis second-quarter 2018 results exceed both earnings and sales estimates. The company completes the acquisition of Abaxis, Inc.

                            Zacks Equity Research

                            Regeneron (REGN) Q2 Earnings Beat on Strong Dupixent Sales

                            by Zacks Equity Research

                            Regeneron (REGN) reports impressive Q2 results on the back of growth in both Eylea and Dupixent sales.

                              Zacks Equity Research

                              Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track

                              by Zacks Equity Research

                              Ophthotech reports narrower-than-expected loss in the second quarter.

                                Zacks Equity Research

                                Regeneron (REGN) Q2 Earnings and Revenues Beat Estimates

                                by Zacks Equity Research

                                Regeneron (REGN) delivered earnings and revenue surprises of 14.98% and 1.98%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

                                  Zacks Equity Research

                                  Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More

                                  by Zacks Equity Research

                                  Let's see how these pharma/biotech stocks are poised ahead of their scheduled results on Aug 2.

                                    Zacks Equity Research

                                    What's in Store for Adverum (ADVM) This Earnings Season?

                                    by Zacks Equity Research

                                    On Adverum's (ADVM) second-quarter 2018 conference call, investor focus will be on the company's progress with its pipeline candidates.

                                      Zacks Equity Research

                                      Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss

                                      by Zacks Equity Research

                                      Sanofi (SNY) beats earnings but misses on sales in the second quarter of 2018 owing to currency headwinds and struggling diabetes and cardiovascular unit.

                                        Zacks Equity Research

                                        Zoetis (ZTS) Gears Up for Q2 Earnings: What's in Store?

                                        by Zacks Equity Research

                                        We expect Zoetis (ZTS) to throw more light on its Abaxis acquisition plans and other pipeline updates during second-quarter 2018 earnings call.

                                          Zacks Equity Research

                                          Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?

                                          by Zacks Equity Research

                                          Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) second-quarter earnings call.

                                            Zacks Equity Research

                                            REGN vs. LGND: Which Stock Should Value Investors Buy Now?

                                            by Zacks Equity Research

                                            REGN vs. LGND: Which Stock Is the Better Value Option?

                                              Zacks Equity Research

                                              Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study

                                              by Zacks Equity Research

                                              Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.

                                                Zacks Equity Research

                                                Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes

                                                by Zacks Equity Research

                                                Amgen's (AMGN) Repatha significantly reduces LDL-C and non-HDL-C in patients with type II diabetes and hypercholesterolemia or mixed dyslipidemia.

                                                  Zacks Equity Research

                                                  Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

                                                  by Zacks Equity Research

                                                  Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.